STOCK TITAN

NextCure (NXTC) Stock News, May 6, 2020

NXTC NASDAQ

NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.

Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.

Rhea-AI Summary

NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, will present at the BofA Securities Virtual Health Care Conference on May 13th at 9:00 am Eastern time. The event will be accessible via a live audio webcast on the company's website, with a replay available two hours post-event for 30 days. NextCure focuses on developing innovative immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
conferences

FAQ

What is the current stock price of NextCure (NXTC)?

NextCure (NXTC) last closed at $6.70.

What is the market cap of NextCure (NXTC)?

The market cap of NextCure (NXTC) is approximately $30.7M.